ATE486960T1 - Fkbp51: ein neues ziel für die therapie mit antidepressiva - Google Patents
Fkbp51: ein neues ziel für die therapie mit antidepressivaInfo
- Publication number
- ATE486960T1 ATE486960T1 AT04765664T AT04765664T ATE486960T1 AT E486960 T1 ATE486960 T1 AT E486960T1 AT 04765664 T AT04765664 T AT 04765664T AT 04765664 T AT04765664 T AT 04765664T AT E486960 T1 ATE486960 T1 AT E486960T1
- Authority
- AT
- Austria
- Prior art keywords
- fkbp51
- antidepressant therapy
- new target
- sample
- antidepressant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03026953 | 2003-11-25 | ||
PCT/EP2004/010857 WO2005054500A1 (en) | 2003-11-25 | 2004-09-28 | Fkbp51: a novel target for antidepressant therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE486960T1 true ATE486960T1 (de) | 2010-11-15 |
Family
ID=34639261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04765664T ATE486960T1 (de) | 2003-11-25 | 2004-09-28 | Fkbp51: ein neues ziel für die therapie mit antidepressiva |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070298027A1 (de) |
EP (1) | EP1687443B1 (de) |
AT (1) | ATE486960T1 (de) |
DE (1) | DE602004029923D1 (de) |
WO (1) | WO2005054500A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150327523A1 (en) | 2014-05-13 | 2015-11-19 | University Of South Florida | Transgenic mouse model for conditional fkbp51 expression and related methods |
US20180355430A1 (en) * | 2015-04-02 | 2018-12-13 | Hmnc Value Gmbh | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists |
US9399039B1 (en) | 2015-06-30 | 2016-07-26 | University Of South Florida | Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2270197A3 (de) * | 2002-03-26 | 2011-02-16 | Massachusetts Institute of Technology | Ziele, Verfahren und Reagenzien für die Diagnose und Behandlung von Schizophrenie |
US20060188879A1 (en) * | 2002-10-31 | 2006-08-24 | Janssen Pharmaceutica N.V. | Crh responsive genes in cns |
-
2004
- 2004-09-28 AT AT04765664T patent/ATE486960T1/de not_active IP Right Cessation
- 2004-09-28 EP EP04765664A patent/EP1687443B1/de not_active Expired - Lifetime
- 2004-09-28 WO PCT/EP2004/010857 patent/WO2005054500A1/en not_active Application Discontinuation
- 2004-09-28 US US10/580,724 patent/US20070298027A1/en not_active Abandoned
- 2004-09-28 DE DE602004029923T patent/DE602004029923D1/de active Active
Also Published As
Publication number | Publication date |
---|---|
DE602004029923D1 (de) | 2010-12-16 |
EP1687443A1 (de) | 2006-08-09 |
EP1687443B1 (de) | 2010-11-03 |
US20070298027A1 (en) | 2007-12-27 |
WO2005054500A1 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peters et al. | The transcriptional landscape of age in human peripheral blood | |
Perera et al. | The missing association: sequencing‐based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans | |
Menni et al. | Circulating proteomic signatures of chronological age | |
Cheishvili et al. | Identification of an epigenetic signature of osteoporosis in blood DNA of postmenopausal women | |
Kawano et al. | Klotho gene polymorphisms associated with bone density of aged postmenopausal women | |
US20170051350A1 (en) | Method and system to predict response to treatments for mental disorders | |
US20210005327A1 (en) | Method and system for personalized, molecular based health management and digital consultation and treatment | |
Kopp et al. | Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis | |
ATE414180T1 (de) | Verwendung der gene kir2.3 und drd2 als molekulare marker zur diagnose von schizophrenie | |
EP3719140A1 (de) | Nichtinvasive diagnose von implantatabstossungen bei patienten mit organtransplantaten | |
Spector et al. | Association between a variation in LRCH1 and knee osteoarthritis: a genome‐wide single‐nucleotide polymorphism association study using DNA pooling | |
Nikopensius et al. | Variation in FGF1, FOXE1, and TIMP2genes is associated with nonsyndromic cleft lip with or without cleft palate | |
Nielson et al. | Identification of hip BMD loss and fracture risk markers through population‐based serum proteomics | |
Yang et al. | Expression signatures of long non-coding RNA and mRNA in human traumatic brain injury | |
DK1809767T3 (da) | Fremgangsmåde og sammensætning til forudsigelse reaktionen på warfarin | |
Reppe et al. | Omics analysis of human bone to identify genes and molecular networks regulating skeletal remodeling in health and disease | |
Ahmad et al. | CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers | |
Tolkachov et al. | Loss of the hematopoietic stem cell factor GATA2 in the osteogenic lineage impairs trabecularization and mechanical strength of bone | |
Sellebjerg et al. | Prediction of response to interferon therapy in multiple sclerosis | |
Tanisawa et al. | Exome-wide association study identifies CLEC3B missense variant p. S106G as being associated with extreme longevity in East Asian populations | |
Levchenko et al. | A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia | |
Messner et al. | Circulating miRNAs respond to denosumab treatment after 2 years in postmenopausal women with osteoporosis—the MiDeTe study | |
ATE486960T1 (de) | Fkbp51: ein neues ziel für die therapie mit antidepressiva | |
Ibdah et al. | Impact of PCSK9, WDR12, CDKN2A, and CXCL12 polymorphisms in Jordanian cardiovascular patients on warfarin responsiveness and sensitivity | |
Kitawaki et al. | Synergistic effect of interleukin‐6 promoter (IL6− 634C/G) and intercellular adhesion molecule‐1 (ICAM‐1 469K/E) gene polymorphisms on the risk of endometriosis in Japanese women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |